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Abstract
Drug-drug interactions (DDIs) are a major cause of pre-
ventable hospitalizations and deaths. Predicting the occur-
rence of DDIs helps drug safety professionals allocate in-
vestigative resources and take appropriate regulatory action
promptly. Traditional DDI prediction methods predict DDIs
based on the similarity between drugs. Recently, researchers
revealed that the predictive performance can be improved by
better modeling the interactions between drug pairs with bi-
linear forms. However, the shallow models leveraging bilin-
ear forms suffer from limitations on capturing complicated
nonlinear interactions between drug pairs. To this end, we
propose Multi-Label Robust Factorization Autoencoder (ab-
breviated to MuLFA) for DDI prediction, which learns a rep-
resentation of interactions between drug pairs and has the ca-
pability of characterizing complicated nonlinear interactions
more precisely. Moreover, a novel loss called CuXCov is de-
signed to effectively learn the parameters of MuLFA. Fur-
thermore, the decoder is able to generate high-risk chemical
structures of drug pairs for specific DDIs, assisting pharma-
cists to better understand the relationship between drug chem-
istry and DDI. Experimental results on real-world datasets
demonstrate that MuLFA consistently outperforms state-of-
the-art methods; particularly, it increases 21.3% predictive
performance compared to the best baseline for top 50 fre-
quent DDIs. We also illustrate various case studies to demon-
strate the efficacy of the chemical structures generated by
MuLFA in DDI diagnosis.
Introduction
Drug-drug interactions (DDIs) are common situations in
which a drug affects the efficacy and safety of another drug
when both are administered together, resulting in many ad-
verse drug reactions (ADRs) that may cause severe injuries
or even be responsible for deaths (Qato et al. 2016). Most
DDIs are discovered by accident once a drug is already on
the market (Percha and Altman 2013). However, early detec-
tion of DDIs at preclinical stage based on data such as drug
chemical structures helps drug safety professionals allocate
investigative resources and take appropriate regulatory ac-
tion (Zhang et al. 2015). In fact, predicting DDIs based on
chemical structures is possible since the concept that similar
chemical structures bring about similar biological properties
has been employed over the years by medicinal chemists
(Traphagen 2002; Gedeck and Lewis 2008). With the ac-
cumulation of massive adverse events data caused by DDI
collected by systems such as FDA Adverse Event Reporting
System (FAERS)1, using computational methods to predict
DDI becomes feasible, and DDI prediction is drawing in-
creasing attention of the AI research community.
Since ADRs (e.g., Nausea, Emesis, High blood pressure,
etc.) associated with DDIs are important for both clinical
and pharmaceutical decisions (Vilar, Friedman, and Hripc-
sak 2017), we can classify DDIs into different types accord-
ing to different ADRs in DDI prediction. The DDI predic-
tion problem studied in this paper is defined as: Predicting
the occurrence of different types of DDIs between a pair of
drugs based on the drug features (e.g., chemical structures).
In literature, similarity-based methods have been widely
applied for DDI prediction (Vilar et al. 2012; Zhang et al.
2015; Abdelaziz et al. 2017; Kastrin, Ferk, and Leskoek
2018). These methods first calculate the similarities between
each pair of drugs based on independently extracted drug
features, and then based on those similarities, they predict
the type of DDIs between drug pairs. The idea of the pre-
diction is that, if drug A is similar to drug B, then the drugs
that have DDIs with drug A are likely to have the same type
of DDIs with drug B. Recently, researchers prove that the
predictive performance can be improved by better modeling
the interactions between drug pairs by bilinear forms (Jin et
al. 2017). Despite the impressive results achieved with this
approach, the question remains as to whether there is a bet-
ter approach that could be used to capture the complicated
nonlinear interactions between drug pairs more precisely.
Nowadays, deep representation learning methods has
been found advantageous in modeling the complicated non-
linear relations (Krizhevsky, Sutskever, and Hinton 2012;
Collobert et al. 2011). DDI prediction is actually a multi-
label classification problem. A natural idea is to harness the
power of representation learning to learn a representation of
interactions between drug pairs that is efficient for classifi-
cation. With adequate labeled data, supervised methods are
encouraged to represent the classes of DDIs in a linearly sep-
arable way. However, of all possible combinations of two
drugs, only a small proportion of drug pairs are labeled with
DDIs. With insufficient labeled data, the supervised algo-
rithms suffer severe overfitting and would achieve low pre-
dictive performance. On the other hand, unsupervised algo-
1https://open.fda.gov/data/faers/
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rithms such as autoencoders allow us to exploit information
hidden in unlabeled data and therefore improve performance
of DDI prediction. However, the representations learnt by
unsupervised methods would in general entangle factors re-
lated to the types of DDIs with other class-irrelevant factors
and therefore introduce undesired bias for DDI prediction.
The aforementioned analysis inspires us that if we manage
to disentangle the categorization factors across all factors,
then we may use a supervised learning signal to train the
representation of categorization factors. At the same time
an unsupervised learning signal could be employed to ex-
ploit hidden information from large unlabeled data, regular-
izing the supervised learning process and thereby enhanc-
ing the generalization of model by restraining overfitting.
The single-label learning method factorization autoencoder
(FAE) (Cheung et al. 2015) introduced a dimerous represen-
tation. FAE considers the class label to be part of the repre-
sentation and the remaining part encode the class-irrelevant
factors. To disentangle the categorization factors across all
latent factors, FAE introduced a mini-batch based cross-
covariance loss termed XCov that penalizes the covariance
matrix of each dimension in the class-relevant coding part
and each dimension in the class-irrelevant coding part.
However, simply extending the vanilla FAE to high-
dimensional multi-label situations such as DDI prediction
would fail to achieve the best result. The reason is that XCov
estimates the cross-covariance in every mini-batch sepa-
rately. When the batch size is small, the cross-covariance
estimator employed by XCov would result in gradient de-
scent directions with large variance and thus hurt the perfor-
mance. On the other hand, a large batch size method tends
to converge to sharp minimizers of the training function and
result in a degradation in the quality of the model as mea-
sured by the ability to generalize (Keskar et al. 2017). We
introduce a novel mini-batch based robust cumulative cross-
covariance loss CuXCov that approximates the full-batch
statistics, which guarantees a more accurate estimation and
allows for better classification performance as well as robust
representations of interactions between drug pairs.
The decoder of the autoencoder can be utilized as a fea-
ture generator. With designed fabricared inputs, the genera-
tor could output feature vector associated with specific cat-
egory. In the context of DDI prediction, the generator could
output vectors describing high-risk chemical structures as-
sociated with specific types of DDIs and therefore providing
hints for drug research and development process.
In summary, our contributions are summarized as follows:
• We proposed Multi-Label Robust Factorization
Autoencoder (called MuLFA) for DDI prediction.
MuLFA inherits the puissant expressing power of deep
neural network to characterize the complicated nonlin-
ear interactions between drug pairs and is capable of
leveraging hidden information in unlabeled data.
• We proposed a robust cumulative cross-covariance loss
CuXCov that approximate the full-batch statistics, which
is designed to effectively learn the parameters of MuLFA
by disentangling categorical factors across latent factors
and thus improving the classification performance.
• We construct a dimerous representation, with which we
could generate high-risk chemical structures for specific
types of DDIs, assisting pharmacists to better understand
the relationship between drug chemistry and DDI and pro-
viding hints in drug research and development process.
• Experimental results on real-world datasets demonstrate
that MuLFA consistently outperforms state-of-the-art
methods; particularly, it increases 21.3% predictive per-
formance compared to the best baseline for top 50 fre-
quent DDIs. We also illustrate various case studies to
demonstrate the efficacy of the chemical structures gen-
erated by MuLFA in DDI diagnosis.
Related Work
In literature, there has been a long line of studies in DDI pre-
diction based on preclinical data. From the methodological
perspective, the most representative DDI prediction methods
are two-stage similarity-based methods. Firstly, drug fea-
tures are extracted for each drug independently, based on
which similarites are calculated for all drug pairs. Secondly,
based on the idea that similar drugs are also biologically
similar, different strategies are employed to predict DDIs
based on the similarites between drugs, e.g., nearest neigh-
bor method (Vilar et al. 2012), label propagation method
(Zhang et al. 2015), link prediction method (Abdelaziz et
al. 2017; Kastrin, Ferk, and Leskoek 2018). Recently, re-
searchers proved that the predictive performance can be im-
proved by better modeling the interactions between drug
pairs by bilinear forms (Jin et al. 2017). However, the shal-
low model being used suffers from limitations on capturing
complicated nonlinear interactions between drugs pairs.
Inspired by the success of deep representation learning
methods (Krizhevsky, Sutskever, and Hinton 2012; Col-
lobert et al. 2011), we introduce a method to better capture
the complicated interaction relationship between drug pairs
as well as leveraging hidden information in unlabeled data.
Some previous works try to employ additional preclin-
ical data, such as targets and enzymes, to enhance DDI
prediction (Cheng and Zhao 2014; Takeda et al. 2017;
Zhang et al. 2017). However, such additional data are not
always available for all drugs of interest (Abdelaziz et al.
2017), limiting the usage scope of those methods. In future,
we will consider how to incorporate more preclinical drug
features, if such extra data can be obtained.
Preliminaries
We first define some notations to prepare our method.
Definition 1. Drug Chemical Structure Data
The drug chemical structure data contains substructure
profiles of m drugs. Define set A as A = {d1, d2, ..., dm}.
The feature vector describing chemical structure of drug dp
is represented by a l-dimensional vector Dp.
Definition 2. Chemical Structure Vector of a Pair of Drugs
Let B denote the set of all possible drug pairs in chemical
structure data, i.e., B = {(dp, dq)|dp, dq ∈ A, 1 ≤ p < q ≤
m}. The chemical structure vector dpq of drug pair (dp, dq)
is the concatenation of substructure profile vectors Dp and
Dq , namely, dTpq=(D
T
p ,D
T
q ).
Definition 3. DDI Data
The DDI data contains n drugs and v types of DDIs.
We denote C = {d˜1, d˜2, ..., d˜n} as the set of n drugs and
R = {r1, r2, ..., rv} as the set of v types of DDIs. Each
type of DDI event corresponds to a specific type of ad-
verse drug reaction2. For a given type of DDI event ri ∈
R, i = 1, 2, ..., v, the data only records credible drug pairs
that could be the causing factor. We define set D as D =
{(d˜p, d˜q)|d˜p, d˜q ∈ C, 1 ≤ p < q ≤ n, d˜p and d˜q are re-
ported to be associated with at least one ri, i = 1, 2, · · · , v}.
We denote the set of drug pairs associate with ri as Ei,
Ei ⊆ D, i = 1, 2, ..., v.
Definition 4. Set of Labeled Drug Pairs and Set of Unla-
beled Drug pairs
We let setD be the set of labeled drug pairs for all v tasks.
And set F = B −D be the set of unlabeled drug pairs3.
Definition 5. Set of Positive Samples and Set of Negative
Samples for occurrence of the i-th Type of DDI ri
Let set Ei be the set of positive samples and set Gi =
D − Ei be the set of negative samples for task ri.
Problem Statement
The problem of DDI prediction is formulated as follows.
Input:
• The set of chemical structure vectors {dk}|B|k=1,4 where
dk = dpq for some p and q such that(dp, dq) ∈ B.
• DDI training data: {ri}vi=1 and the corresponding sets of
positive samples and negative samples, {Ei,Gi}vi=1.
Output: Predicted occurrence of ri of testing drug pairs for
each type of DDI event i = 1, 2, · · · , v.
Factorization Autoencoder and XCov Loss
Researchers have proposed a semi-supervised factorization
autoencoder that could be used in single-label learning(Che-
ung et al. 2015). Specifically, given an input x and its cor-
responding one-hot class label vector y for a dataset D,
FAE learns the high-level representation (the last-layer of
the encoder) in the form of concatenation of two vectors,
i.e., fΘ(x)T = (yˆT , zT ). FAE considers the class label to
be part of the high-level representation of its correspond-
ing input. Using class labels, FAE incorporates supervised
learning to a subset of high-level representation, transform-
ing them into observed variable yˆ. The remaining subset z
accounts for the remaining variation of dataset. To disen-
tangle the categorization factors from other latent variables,
FAE adds a mini-batch based cross-covariance loss (termed
XCov). XCov loss prevents vector z from encoding input
2ADRs caused by 2 co-administered drugs rather than ADRs
caused by a single drug.
3In general, databases recording chemical structure collect as
much information as possible. It is reasonable to assume D ⊆ B.
4 |S| denotes the cardinality of set S. {ei}Li=1 denotes a set and
the index of element ei in set ranges from 1 to L.
variations due to class label by penalizing the covariance
matrix of each dimension in the class-relevant coding part
and each dimension in the class-irrelevant coding part.
LXCov =
1
2
∑
ij
[
1
N
∑
s
(yˆsi − ¯ˆiy)(zsj − z¯j)]2. (1)
N is mini-batch size, and ¯ˆiy, z¯i denote means over exam-
ples. s is an index over examples and i, j index feature di-
mensions. In our problem, FAE cannot be directly used for
two reasons: (1) FAE is a single-label learning method. (2)
XCov estimates cross-covariance separately in each mini-
batch and could result in descent directions with large vari-
ance. To this end, we extend the FAE to address the two
issues in next sections.
Methods
Framework Overview
The overall neural network within MuLFA is built with an
autoencoder structure. Figure 1 shows the architecture of
our proposed method. The network consists of H + 1 lay-
ers where H is an even number. The first H2 hidden lay-
ers are encoders to learn a representation of each input and
the last H2 hidden layers are decoders to reconstruct the in-
put. For ease of illustration, we first fix some notations. Let
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Figure 1: The architecture of MuLFA.
L(0) = d ∈ R2l denote an input to the first layer and
L(h) = t(h)((W(h))TL(h−1) + b(h)) ∈ Rdh (2)
be the output of the h-th layer, h = 1, 2, · · · , H . dh denotes
the dimension of the output at the h-th layer and t(h)s are
activation functions, which we take ReLU 5 for all hidden
layers except the high-level representation layer, i.e., for h =
5We’ve tested other activations such as tanh and sigmoid by 10-
fold cross-validation, among which ReLU performed best.
H
2 ,
L(
H
2 ) =
(
Yˆ
Z
)
= ((yˆ1, · · · , yˆv)T , (z1, · · · , zu)T )T ∈ Rv+u.
(3){
yi = Sigmoid((W
(H2 )
i )
TL
H
2 −1 + b(
H
2 )
i ), i = 1, 2, · · · , v;
zi = (W
(H2 )
v+j )
TL
H
2 −1 + b(
H
2 )
v+j , j = 1, 2, · · · , u.
(4)
Where W
H
2 = (W(
H
2 )
1 ,W
(H2 )
2 , · · · ,W(
H
2 )
v+u) and b
H
2 =
(b
H
2
1 , b
H
2
2 , · · · , b
H
2
v+u)
T . The output of the top layer is LH .
We define the function of encoder as fΘ and the function
of decoder as gΦ. Θ and Φ denote the parameter space of
encoder and decoder respectively.
fΘ(d) =
(
Yˆ
Z
)
∈ Rv+u, gΦ(fΘ(d)) = LH ∈ R2l. (5)
Our goal of representation learning is to learn a represen-
tation (L(
H
2 ))T = (Yˆ
T
,ZT ) that isolates the categorization
factors from other latent factors. Yˆ codes the class labels
of the input d with yˆi denoting the probability of the occur-
rence of the i-th event ri. Z codes the class-irrelevant factors
to serve for semi-supervised learning by preserving as many
factors of variation in the data as possible for the sake of
reconstruction of input d.
For i = 1, 2, · · · , v , the learning of yˆi can be viewed as
a task ri. In DDI prediction, each yˆi is corresponding to a
type of DDI event. Actually, different types of DDI events
are related. For example, if a specific drug pair causes Nau-
sea, then the specific drug pair is likely to cause Emesis.
Thus the learning of Yˆ can benefit from Multi-task learn-
ing for better exploiting the relatedness among tasks. (Caru-
ana 1997) characterized multi-task learning as an approach
to inductive transfer that improves generalization and gen-
eralization error bounds (Baxter 1995) by using the domain
information contained in the training signals of related tasks
as an inductive bias. Regarding outputs of layers {Lh}H/2−1h=1
as shared representation, hard under-sampled types of DDIs
that could not be learnt in isolation are able to be learnt, and
what is learnt for each task help other tasks be learnt better.
To factor the entangled source of variation relevant for
categorization apart from other factors across the representa-
tion L(
H
2 ), We introduce a mini-batch based robust cumula-
tive cross-covariance CuXCov loss to approximate the full-
batch statistics, aiming at minimizing the entries in cross-
covariance matrix of Yˆ and Z for all samples.
Loss Function
We now present details of how to train our model.
Goal The training objective of MuRFA is to minimize the
weighted integration of 3 losses:
min
Θ,Φ
LCls + βLCuXCov + γLRcnst. (6)
Where hyperparameters β > 0 and γ > 0 control relative
weights of LCuXCov and LRcnst over LCls. LCls penal-
izes the discrepancy between groundtruth labels and pre-
dicted occurrence probabilities of samples in labeled sets.
LCuXCov penalizes the estimated values of entries in cross-
variance matrix of Yˆ and Z. LRcnst is the general recon-
struction error in autoencoders, penalizing the discrepancy
between input d and gΦ(fΘ(d)) for all training samples.
CuXCov Loss When the number of different classes is
large, (e.g., in DDI prediction, the known number of differ-
ent classes of DDIs is more than 1,000.) the cross-covariance
matrix between Yˆ and Z would in general require a large
sample size to achieve an accurate estimation. However, the
XCov loss in (1) estimates cross-covariance separately in
each mini-batch and could result in descent directions with
large variance. To address this issue, inspired by (Chang, Xi-
ang, and Hospedales 2018), we propose a cumulative loss
CuXCov that approximates the full-batch cross-covariance
matrix. This cumulative strategy can trace back to (Welford
1962), where the author proposed an accurate, one-pass, in-
cremental approach to estimate the second central moment.
Let Σkf ,Σ
k
c ,Σ
k
m,Σ
k
a denote the full, cumulative, mini-batch,
approximate cross-covariance estimator at the k-th training
step respectively. The approximation works as follows:{
Σkc = αΣ
k−1
c + Σ
k
m, with Σ
0
c = 0,
pk = αpk−1 + 1, with p0 = 0.
(7)
Where α ∈ [0, 1] is the decay rate. Then let
Σka = Σ
k
c/p
k. (8)
Σka would start converging to Σ
k
f as k-th gets larger.
Let [
˜ˆY
Z˜
]
∈ R(v+u)×N (9)
denote the high-level representation over a mini-batch
with size N , where ˜ˆY = (Yˆ1, Yˆ2, · · · , YˆN ), and Z˜ =
(Z1,Z2, · · · ,ZN ).
We write mini-batch cross-covariance estimator in matrix
form
Σkm = 1/N(
˜ˆY(I−eeT ))(Z˜(I−eeT ))T = 1/N ˜ˆYHZ˜T ∈ Rv×u.
(10)
Where e ∈ RN is a column vector with all entries being 1,
I is the identity matrix, and H = (I − eeT )(I − eeT )T ∈
RN×N . From (7), (8) and (10), we have
Σka = 1/p
k(αΣk−1c + 1/N
˜ˆYHZ˜
T
) ∈ Rv×u. (11)
Our goal is to minimize all entries in Σka. We define CuX-
Cov loss as:
LCuXCov = trace((Σka)TΣka)/2. (12)
The gradient of CuXCov loss with respect to ˜ˆY and Z˜ is:
∂LCuXCov
∂Z˜
=
α
N(pk)2
(Σk−1a )
T ˜ˆYH+
1
N2(pk)2
Z˜HT ˜ˆYT ˜ˆYH.
(13)
∂LCuXCov
∂
˜ˆY
=
α
N(pk)2
Σk−1a Z˜H
T +
1
N2(pk)2
˜ˆYHZ˜
T
Z˜HT .
(14)
Classification Loss Our model can achieve multi-label
learning. The learnt Yˆ = (yˆ1, yˆ2, · · · , yˆv)T in representa-
tion for each input d predicts the probabilities of occurrence
of ri for i = 1, 2, · · · , v. We use the labeled set for each task
to supervise the training of yˆis.
LCls = −
∑
ds∈Ei∪Gi
v∑
i=1
(λysi log(yˆ
s
i ) + (1− ysi )log(1− yˆsi ))
(15)
Where i indexes tasks and s indexes examples. ysi is the label
of s-th sample in labeled set with 1 coding the occurrence of
event ri and 0 otherwise. λ > 1 denotes the relative confi-
dence of positive samples over negative samples. In the DDI
prediction case, we record a drug pair associated with a type
of DDI ri if the drug pair causes the corresponding adverse
drug reaction. And no record of a drug pair associated with
ri does not induce the conclusion that the drug pair would
never cause the corresponding adverse drug reaction. Thus,
it is more appropriate to treat positive samples and negatives
samples discriminatively, and put larger weights on positive
samples.
Reconstruction Loss We often have a large amount of
unlabled training data and relatively little labeled training
data. To better explore information contained in unlabeled
data, the architecture of autoencoder allows us to introduce
the reconstruction loss over the whole training data.
LRcnst =
∑
di∈B
||di − gΦ(fΘ(di))||2. (16)
Where B denotes the whole training set. Reconstruction loss
also acts as a regularization term for the classification loss.
Canonical Samples Generator
After the auto-encoder is trained,
Θˆ, Φˆ = argmin
Θ,Φ
LCls + βLCuXCov + γLRcnst. (17)
decoding functionGΦˆ(L
H) can be used as sample generator
given a high-level representation LH0 . Formally, we define
Definition 6. The Canonical Sample with respect to the i-th
Category: Let Yˆi be a vector with all entries being 0 except
the i-th entry being 1. Let
Zˆ = EB(Z|Θˆ, Φˆ), Ci = GΦˆ(
(
Yˆi
Zˆ
)
) (18)
We name Ci the feature vector of the canonical sample
with respect to the i-th category, for i = 1, 2, · · · , v. The
corresponding sample is named as the canonical sample
with respect to the i-th category.
Take the last u entries of 1/|B| ∑
di∈B
fΘˆ(di) as
˜ˆZ to esti-
mate Zˆ. Then an approximation of Ci is C˜i = GΦˆ(
(
Yˆi
ˆ˜Z
)
).
In DDI prediction, when the inputs of MuLFA are chemi-
cal structure vectors of drug pairs, the canonical sample with
respect to the i-th type of DDI event would be approximate
canonical chemical structures of a pair of drugs that could
jointly lead to the corresponding adverse drug reaction.
Experiments
Datasets
DDI Data The DDI data we use is from Twosides
database6 (Tatonetti et al. 2012). It contains 645 drugs and
1318 types of DDIs, and in total 63473 drug pairs associ-
ated with DDI reports that makes the labeled set D with
|D| = 63473.
Drug Chemical Structure Data The chemical structure
features we use are extracted from Pubchem7 substructure
fingerprint, and are binary coded as an 881-bit feature vec-
tor, each bit representing a Boolean determination of the
presence of a substructure. For fair comparison, we only
extract structure features of all drugs appeared in Twosides
database, namely, A = C and |B| = (6452 ).
Experiment I On Classification Performance
Methods for Comparison
Baselines We compared our model with the following
methods.
• Nearest Neighbor (NN) method in (Vilar et al. 2012).
• Label Propagation (LP) method in (Zhang et al. 2015).
• Dyadic Prediction (DP) method in (Jin et al. 2017).
Variants of our methods We also studied the effect of
different components proposed in our method. The networks
were trained by back-propagation via Adam optimizer.
• MuLFA: Our proposed model.
• MuLFA-R: Our proposed model without considering the
reconstruction penalty.
• MuLFA-X: Our proposed model without considering the
cross-covariance penalty.
• MuLFA-X+ Our proposed model without Z in high-level
representation, leading to no cross-covariance penalty.
Evaluations We randomly selected 10% of drugs and
masked all DDIs associated with these drugs for testing in
alignment with (Zhang et al. 2015). DDIs associated with
drugs not in testing set are used for training all models and
we use 10-fold cross-validation to tune all hyperparameters
of different methods. For testing data, we evaluate all meth-
ods on different collections of DDIs. For a given collection
of DDIs, we randomly selected 50% of the testing set for
evaluation and repeated the selection-evaluation process for
50 times. We report the mean and standard deviation of the
Area Under Precision-Recall Curve(AUPR) over 50 repe-
titions. DDI data is highly unbalanced with small positive
sample sets and much larger negative sample sets for dif-
ferent types of DDIs. It was shown in (Davis and Goadrich
2006) that the area under Receiver Operating Characteristic
curve (AUROC) is not appropriate for unbalanced data and
metrics such as AUPR should be used instead.
We adopt a different strategy in constructing the sets of
negative samples compared with DR. DR took the comple-
ment of Twosides DDI interactions {Gi ∪ F}vi=1 as nega-
tive samples, while we took {Gi}vi=1 as negative samples
and F as the unlabeled set in our method. We examined the
6http://tatonettilab.org/resources/tatonetti-stm.html
7https://pubchem.ncbi.nlm.nih.gov/
drug pairs in the F and found some drug pairs should not be
co-administered, e.g., Carbamazepine (ID=2554) and Isoni-
azid (ID=3767) are a pair of drugs in F . Concurrent use of
Carbamazepine and Isoniazid may result in increased carba-
mazepine exposure and increased risk of isoniazid-induced
hepatotoxicity (Wright, Stokes, and Sweeney 1982). For
drug pairs in F constructed from Twosides, no credible data
can be observed and we are not able to judge whether the
other drug pairs in F interact or not, thus we take F as the
unlabeled set. For all methods, we utilized DDI interactions
from Twosides {Ei}vi=1as positive samples.
Table 1: AUPR of MuLFA against Baselines.
Methods Top 50 DDIs Top 51-100 DDIs Top 101-150 DDIs
NN 0.367(0.0030) 0.265(0.0023) 0.224(0.0028)
LP 0.360(0.0031) 0.254(0.0025) 0.211(0.0029)
DR 0.375(0.0025) 0.272(0.0019) 0.233(0.0026)
MuLFA 0.455(0.0029) 0.313(0.0027) 0.270(0.0033)
Table 2: AUPR of MuLFA against its Variants.
Methods Top 50 DDIs Top 51-100 DDIs All DDIs
MuLFA-R 0.424(0.0035) 0.293(0.0028) 0.236(0.0023)
MuLFA-X 0.429(0.0028) 0.294(0.0026) 0.243(0.0025)
MuLFA-X+ 0.423(0.0028) 0.288(0.0029) 0.241(0.0020)
MuLFA 0.455(0.0029) 0.313(0.0027) 0.278(0.0019)
Results and Discussion Table 1 and 2 compare the per-
formance of the proposed method against competing meth-
ods and the variants of MuLFA on different of collections of
DDIs. The TopX1−X2 DDIs in the table denotes the collec-
tion of X1-th to X2-th most frequent DDIs. The tables show
that MuLFA consistently achieves higher AUPRs as com-
pared to all competing methods at different settings. More
concretely, from Table 1 we can see that DR and MuLFA
outperform NN and LP consistently by better modeling the
interactions between drug pairs. As the tasks become harder,
namely, when the labeled sets become more and more unbal-
anced, the performances of similarities-based methods de-
cay faster for failing to exploit the relatedness among tasks.
Furthermore, our proposed method achieves improvement
consistently over DR by up to 21.3% because the deep neu-
ral network framework is able to capture the complicated
nonlinear interaction relationship between drug pairs more
precisely. Table 2 shows the performances of MuLFA and
its variants. MuLFA-R is a supervised model which fails
to leverage the information contained in the large unla-
beled set. MuLFA-X outperforms MULFA-X+ consistently
demonstrating the effectiveness of including Z for encoding
the class-irrelevant factors. MuLFA outperforms MuLFA-X
significantly demonstrates the necessity of disentangle the
categorization factors across all latent factors.
Sensitivity Analysis We study the sensitivity of two im-
portant parameters in our approach. The decay rate α in
CuXCov loss and the relative confidence of positive sam-
ples over negative samples λ. We evaluate our model by grid
Figure 2: AUPRs of different combinations of (α, λ).
search as shown in figure 2, computing AUPRs of predict-
ing 1318 DDIs simultaneously for different combinations of
(α, λ). The best combination is (α, λ) = (0.3, 4). Small val-
ues of α lead to estimations that lose too much information
about early steps, while large values lead to too much em-
phasis on early steps and gain deficient information of a new
batch. Small values of λ make the model fail to discrimi-
nate the positive samples from less reliable negative sam-
ples, while large values of λ prevent the model predicting an
example being positive because of the high penalty.
CuXCov Loss vs XCov Loss We study the performances
of models leveraging CuXCov loss against models leverag-
ing XCov loss. Note that CuXCov loss degenerates to XCov
loss when α = 0. For α = {0, 0.3}, we evaluate the predic-
tive performances of 2 losses as shown in Figure 3. In the left
panel of Figure 3, we study the influence of number of tasks
on performance for mini-batch size being 200. We evaluate
the methods under different dimensions of Yˆ, i.e., the num-
ber of considered DDIs, from 400 to 1200 with step length
being 200. The result demonstrates that CuXCov model out-
performs XCov model consistently and decays slower than
XCov model as dimension of Yˆ is getting higher. In the right
panel of Figure 3, we study the influence of batch size on
performance for all 1318 DDIs. We evaluate the methods un-
der different batch sizes ranging from 50 to 3200. The result
demonstrates that CuXCov model outperforms XCov model
consistently. The performances of two models are increas-
ing as batch size getting larger at first for better estimation
of cross-covariance with smaller estimation variance. As the
batch size continually getting larger, the performances of
two models decay because of the degradation of general-
ization caused by convergence to sharp minimizers of the
training function (Keskar et al. 2017).
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Figure 3: AUPRs of model leveraging CuXCov against model
leveraging XCov loss in different settings.
Experiment II
Case Studies On Generated Chemical Structures
On Generated Canonical Chemical Structures of DDIs
with High Co-occurrence Different types of DDIs are re-
lated. Usually, the ingenerate biological properties of DDIs
with high co-occurrence are similar or even identical. For
example, Sinus Tachycardia frequently co-occurs with Nau-
sea and both of them can be activated by increased cat-
echolamine release (Koch et al. 1990). Moreover, similar
chemical structures may bring about similar medication ef-
fect mechanisms (Traphagen 2002), which may cause DDIs.
Thus it is reasonable to conjecture that the chemical struc-
tures of drug pairs that cause highly frequent co-occurred
DDIs should be similar to each other. The left panel of fig-
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Figure 4: Visualization of generated canonical chemical structure
vectors of some chosen DDIs by t-SNE.
ure 4 is the 2-dimensional t-SNE (Maaten and Hinton 2008)
visualization of generated canonical chemical structure vec-
tors of Neumonia, 50 most frequent DDI types co-occur
with Neumonia and 50 least frequent DDI types co-occur
with Neumonia. From the figure we can see that DDIs co-
occur with Neumonia more frequently result in more similar
generated canonical chemical structures. Megacolon, Eating
Disorder and Disorder Perpheral Vascular are 3 randomly
selected types of DDIs with low co-occurrence with each
other, and the right panel of figure 4 is the visualization of
canonical chemical structure vectors of these 3 DDIs accom-
panied with 20 frequent co-occurred DDIs for each respec-
tively. We can see 3 clusters in the embedding space in align-
ment with our conjecture.
On Explanation of Generated Canonical Structures
For better interpretability we first constructed a reference
setby randomly selecting 10% of all drugs from Twosides
database and masked all DDIs associated with these drugs.
We used the hyperparameters tuned in experiment I and
trained MuLFA with the remain data. After the network is
trained, we use the decoder to generate the canonical sam-
ples for top 20 DDIs with highest AUPRs. We consult phar-
macy experts on the generated canonical structures. They
confirmed that two classes of frequent generated high-risk
structures are actually structurally similar to an inhibitor and
a substrate of Cytochromes P450. Inhibitors and substrates
are of high-risk to interact with other drugs. The pharmacy
experts also confirm and explain the efficacy of the gener-
ated chemical structures of drug pairs with respect to DDI
type Hypoventilation.
On Understanding the Frequent Generated High-risk
Structures We compare the feature vectors of the generated
canonical samples with the vectors of drugs in the reference
set, and we record the top 3 nearest neighbors for each gen-
erated drug structure. There are 120 counts in total, among
of which structures resembling Valproic Acid (30/120) and
structures resembling Fentanyl (25/120) are most frequent.
Cytochromes P450 (CYPs) are proteins of the super-
family that functions as an important enzyme system for
drug metabolism. CYPs catalyze a wide range of oxida-
tive reactions and are the most important pathway for drug
metabolism. A drug can act as a substrate, an inducer or
an inhibitor of CYPs. Inducers can increase the activity of
the enzyme, and accelerate the metabolism of itself or other
drugs. Inhibitors can attenuate the activity of the enzyme
and slow down the metabolism of itself or other drugs. In-
hibitors may also increase drug concentration that poses
toxicity risks. Valproic acid is thought as an inhibitor of
CYP450 2C9 (CYP2C9). Co-administration of valproic acid
with drugs that are primarily metabolized by CYP2C9 may
result in increased drug concentration and adverse reactions
would be observed. Fentanyl is the substrate of CYP3A4.
Adverse events may occur if Fentanyl is co-administered
with drugs that are the inducers or inhibitors of CYP3A4.
On Explanation of Generated Canonical Sample We
compare the generated canonical feature vector of DDI
type Hypoventilation with the drugs in reference set and
find Ilopost and Venlafaxine are two most structurally
similar drugs. From the chemical structure perspective,
Iloprost(C22H32O4) is an eicosanoid, derived from the
cyclooxygenase pathway of arachidonic acid metabolism,
functioning as a stable analog of prostacyclin (PGI2). Ilo-
prost is thought to promote benefit in pulmonary arterial
hypertension (PAH) through vasodilation, antiproliferative
effects, and inhibition of platelet aggregation(Baker and
Hockman 2005). Venlafaxine (C17H27NO2) is a cyclohex-
anol and phenylethylamine derivative that functions as a
serotonin-norepinephrine reuptake inhibitor (SNRI). In vitro
studies (Sarma 2010) suggest that Venlafaxine would im-
pact platelet aggregation. When Venlafaxine and Iloprost are
administered together, Venlafaxine would decrease the drug
efficacy of Iloprost by affecting the inhibition of platelet ag-
gregation. Thus hypoventilation would be observed as a con-
sequence of inadequate treatment of PAH.
Conclusion
In this paper, we propose a novel semi-supervised repre-
sentation learning approach MuLFA for DDI prediction.
We construct a dimerous representation for drug pairs, with
which we can not only predict different types of DDIs simul-
taneously but also generate high-risk chemical structures for
specific types of DDIs. We conduct extensive experiments
on large-scale real-world data. The results demonstrate bet-
ter classification performance of MuLFA than state-of-the-
art prediction methods based on chemical structures. We
also illustrate various case studies to demonstrate the effi-
cacy of the chemical structures generated by MuLFA.
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